Jean-Francois Gautier
Overview
Explore the profile of Jean-Francois Gautier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
139
Citations
3402
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Camoin M, Mohammedi K, Saulnier P, Hadjadj S, Gautier J, Riveline J, et al.
J Clin Endocrinol Metab
. 2025 Feb;
PMID: 39902910
Context: Intraindividual body-weight variability or cycling is associated with increased risk of chronic kidney disease (CKD) in the general population. Objective: We conducted a retrospective analysis of data from the...
2.
Motino O, Lambertucci F, Joseph A, Durand S, Anagnostopoulos G, Li S, et al.
Cell Death Differ
. 2024 Nov;
32(3):434-446.
PMID: 39550516
Acyl-CoA binding protein (ACBP), also known as diazepam-binding inhibitor (DBI), is an extracellular checkpoint of autophagy. Here, we report that patients with histologically confirmed metabolic-associated steatohepatitis (MASH) or liver fibrosis...
3.
Fagherazzi G, Aguayo G, Zhang L, Hanaire H, Picard S, Sablone L, et al.
Diabetologia
. 2024 May;
67(8):1567-1581.
PMID: 38780786
Aims/hypothesis: Our study aims to uncover glycaemic phenotype heterogeneity in type 1 diabetes. Methods: In the Study of the French-speaking Society of Type 1 Diabetes (SFDT1), we characterised glycaemic heterogeneity...
4.
Ossima A, Brzustowski A, Paradis V, Van Beers B, Postic C, Laouenan C, et al.
Clin Diabetes Endocrinol
. 2024 Apr;
10(1):9.
PMID: 38659082
Background & Aims: Despite its high prevalence in the western world metabolic dysfunction-associated steatotic liver disease (MASLD) does not benefit from targeted pharmacological therapy. We measured healthcare utilisation and identified...
5.
Castera L, Garteiser P, Laouenan C, Vidal-Trecan T, Vallet-Pichard A, Manchon P, et al.
J Hepatol
. 2024 Mar;
81(2):195-206.
PMID: 38548067
Background & Aims: Non-invasive scores have been proposed to identify patients with fibrotic, metabolic dysfunction-associated steatohepatitis (MASH), who are at the highest risk of progression to complications of cirrhosis and...
6.
Julla J, Girard D, Diedisheim M, Saulnier P, Tran Vuong B, Bleriot C, et al.
Circ Res
. 2023 Dec;
134(2):189-202.
PMID: 38152893
Background: Diabetes is a major risk factor for atherosclerotic cardiovascular diseases with a 2-fold higher risk of cardiovascular events in people with diabetes compared with those without. Circulating monocytes are...
7.
Riveline J, Mallone R, Tiercelin C, Yaker F, Alexandre-Heymann L, Khelifaoui L, et al.
Front Neurol
. 2023 Nov;
14:1256984.
PMID: 38020587
Background: Sudomotor dysfunction is one of the earliest manifestations of small fiber neuropathy (SFN), reflecting the alteration of sympathetic C fiber innervation of the sweat glands. Among other techniques, such...
8.
Jacquemier P, Retory Y, Virbel-Fleischman C, Schmidt A, Ostertag A, Cohen-Solal M, et al.
Sci Rep
. 2023 Nov;
13(1):20052.
PMID: 37973963
Glycemic variability remains frequent in patients with type 1 diabetes treated with insulin pumps. Heterogeneous spreads of insulin infused by pump in the subcutaneous (SC) tissue are suspected but were...
9.
Poynard T, Deckmyn O, Peta V, Paradis V, Gautier J, Brzustowski A, et al.
Aliment Pharmacol Ther
. 2023 Aug;
58(9):888-902.
PMID: 37642160
Background: No prospective diagnostic studies have directly compared widespread non-invasive liver tests in patients with type 2 diabetes (T2D) using the intention-to-diagnose method for each of the three main histological...
10.
Kevorkian J, Vandiedonck C, Laganier J, Lopes A, Burlacu R, Feron F, et al.
Minerva Med
. 2023 May;
116(1):75-79.
PMID: 37166204
No abstract available.